Genkyotex SA.

GenKyoTex SA is a France-based company involved in the biotechnology sector. The Company focuses on the development of therapies based on selective inhibition of nicotinamide adenine dinucleotide phosphate oxidase (NOX) enzymes, which cause a range of disease processes, such as fibrosis, inflammation, pain processing, cancer development and neurodegeneration. The Company's pipeline includes GKT831, a NOX inhibitor aimed at primary biliary cholangitis (PBC) and fibrosis; GKT771, a NOX inhibitor mainly aimed at inflammatory pain and angiogenesis, and other NOX inhibitors, which target at central nervous system (CNS), hearing loss and oncology.